Last reviewed · How we verify

NCT05991167

EndeavorRx® Prospective Product Registry ("Expedition EndeavorRx")

Active, enrolled Last updated 27 June 2024
What this trial tests

trial testing EndeavorRx in ADHD in 150 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 June 2022
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorAkili Interactive Labs, Inc.
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment150
Start date1 June 2022
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Akili Interactive Labs, Inc.

Who can join

Eligibility, any sex, with ADHD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The EndeavorRx Prospective Product Registry aims to collect real world data from participants receiving the digital therapeutic, EndeavorRx, under conditions of routine clinical practice.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of EndeavorRx

Trials testing the same drug.

Other recruiting trials for ADHD

Currently open trials in the same condition.

Other Akili Interactive Labs, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05991167.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing